Summarized by Masters of Longevity from Longevity Investors News.
Novo and Lilly reported slower aging-clock readings in treated patients.
Key Takeaways
- Novo's trial showed 2–3 years younger clock readings.
- Lilly's result lacks a placebo comparison and is inconclusive.
- Results were in overweight or diabetic patients and remain unproven.
